Alogliptin benzoate for management of type 2 diabetes - Wikidata - awgldk - TriplyDB

Alogliptin benzoate for management of type 2 diabetes

Alogliptin benzoate for management of type 2 diabetes

http://www.wikidata.org/entity/Q28083933

about

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1.

P2860

Q26785454-F75FE84F-56C1-4132-B4DC-7FDDF6BB6D46 Q36429742-DA43A9C6-A033-4103-97ED-1C141C753B4A Q41191334-926C1268-55DD-49F7-9301-3BA1FB1A8CE4

P2860

Alogliptin benzoate for management of type 2 diabetes

http://www.wikidata.org/entity/Q28083933

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Alogliptin benzoate for management of type 2 diabetes

@ast

Alogliptin benzoate for management of type 2 diabetes

@en

Alogliptin benzoate for management of type 2 diabetes

@nl

type

label

Alogliptin benzoate for management of type 2 diabetes

@ast

Alogliptin benzoate for management of type 2 diabetes

@en

Alogliptin benzoate for management of type 2 diabetes

@nl

prefLabel

Alogliptin benzoate for management of type 2 diabetes

@ast

Alogliptin benzoate for management of type 2 diabetes

@en

Alogliptin benzoate for management of type 2 diabetes

@nl

P1433

Q28083933-4F8DA12E-2FF9-4754-AB96-D62752DEF556

P1476

Q28083933-64D18DCA-6684-41C2-A0C3-ADCB16CF2099

P2093

Q28083933-46008F80-5260-4AD7-9166-CAED6038B534

P275

Q28083933-9FF7ACF1-8BAD-4068-BEB1-D7BF716B3E10

P2860

Q28083933-0357F69B-318C-497B-AAD6-4EB92E07828F

Q28083933-0A44BF88-F7FF-4618-AE84-F2FB7F50FEC4

Q28083933-13980D01-02EE-4A6F-B80B-CEF48FC56802

Q28083933-13BD9811-01FA-458F-A0DD-E0D8AF97AB9A

Q28083933-147C81C8-BBF0-4978-9C7B-1DD40D87C971

Q28083933-14968BD8-497A-4DC6-A993-76C93673BADC

Q28083933-14E44B7E-6A0E-4724-8170-DB0DAB0D0070

Q28083933-1B24406D-87E4-4D1D-986A-02B8100FC769

Q28083933-1E8EAFC9-5888-47CB-ACAB-4200C68CC151

Q28083933-2380C5A8-5A3D-4E73-BF6B-FCF846798AD7

P304

Q28083933-016F3050-F82B-4988-9CD9-9F7EECE9CA02

P31

Q28083933-02094FCF-505F-4931-A9EC-939B34917EB5

Q28083933-57F113FB-B05E-4222-8D7A-224004D486F4

P356

Q28083933-20E0B28F-265A-4E25-B2C8-12A784706DF3

P407

Q28083933-2D1682C5-4450-45EC-96FA-2CC3BD239F6A

P478

Q28083933-891BC9E8-9F39-4D7F-BEFB-16B4EE4316F7

P5008

Q28083933-78A5F044-4103-4F7E-B526-E7C783583401

P577

Q28083933-73DB34E0-1ADD-4546-9541-508425633B27

P698

Q28083933-FCC957BB-5586-4738-901A-D6286F5BFEF9

P921

Q28083933-21D14CCC-BD0B-4670-BA21-80747DEF73D2

Q28083933-21D197CB-06CC-4121-8758-EA413AC5CC2E

Q28083933-5AAAE164-2DD8-497C-8104-2273CC01998C

Q28083933-B92736F6-BFAC-4450-AE7A-6ADD27DD9B82

P932

Q28083933-B72EF5EE-6C45-456B-9D39-3B5EC4813129

P356

P1433

Vascular Health and Risk Management

P1476

Alogliptin benzoate for management of type 2 diabetes

@en

P2093

Yoshifumi Saisho

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

P304

229-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.S68564

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25914541

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

type-2 diabetes

mechanism of action

maturity-onset diabetes of the young

P932

4401208

http://www.w3.org/2001/XMLSchema#string